An opioid antagonist with properties similar to those of NALOXONE; in addition it also possesses some agonist properties. It should be used cautiously; levallorphan reverses severe opioid-induced respiratory depression but may exacerbate respiratory depression such as that induced by alcohol or other non-opioid central depressants. (From Martindale, The Extra Pharmacopoeia, 30th ed, p683)
Levallorphan has been studied across 17 research domains including 💊 Pain, 🌤️ Mood & Depression, 🫁 Respiratory, 🧠 Learning, 🧠 Focus & Attention. The primary research focus is 💊 Pain with 45% of studies addressing this area.
The following compounds share molecular targets with Levallorphan, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Levallorphan is generated deterministically from 289 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.